Paul Tudor Jones's MLTX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 103,516 shares of MoonLake Immunotherapeutics (MLTX) worth $1.36 M, representing 0.00% of the portfolio. First purchased in 2023-Q2, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in MLTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 103,516 shares. Largest reduction occurred in Q4 2024, reducing 31,840 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's MoonLake Immunotherapeutics (MLTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly MoonLake Immunotherapeutics (MLTX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +103,516 | New Buy | 103,516 | $13.18 |
| Q3 2025 | -31,714 | Sold Out | 0 | $0.00 |
| Q2 2025 | +122 | Add 0.39% | 31,714 | $47.20 |
| Q1 2025 | +31,592 | New Buy | 31,592 | $39.07 |
| Q4 2024 | -31,840 | Sold Out | 0 | $0.00 |
| Q3 2024 | +4,667 | Add 17.18% | 31,840 | $50.42 |
| Q2 2024 | -4,238 | Reduce 13.49% | 27,173 | $43.97 |
| Q1 2024 | +1,257 | Add 4.17% | 31,411 | $50.23 |
| Q4 2023 | +13,059 | Add 76.39% | 30,154 | $60.39 |
| Q3 2023 | +3,546 | Add 26.17% | 17,095 | $57.00 |
| Q2 2023 | +13,549 | New Buy | 13,549 | $51.00 |
Paul Tudor Jones's MoonLake Immunotherapeutics Investment FAQs
Paul Tudor Jones first purchased MoonLake Immunotherapeutics (MLTX) in Q2 2023, acquiring 13,549 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held MoonLake Immunotherapeutics (MLTX) for 11 quarters since Q2 2023.
Paul Tudor Jones's largest addition to MoonLake Immunotherapeutics (MLTX) was in Q4 2025, adding 103,516 shares worth $1.36 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 103,516 shares of MoonLake Immunotherapeutics (MLTX), valued at approximately $1.36 M.
As of the Q4 2025 filing, MoonLake Immunotherapeutics (MLTX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in MoonLake Immunotherapeutics (MLTX) was 103,516 shares, as reported at the end of Q4 2025.